Key Highlights
- Partnership to expand molecular testing across European and UK markets.
- Focus on rapid, in-house cancer diagnosis using NGS liquid biopsy panels.
- Pillar’s oncoRevealTM LBx panels offer high sensitivity with results in less than three days.
- Scalable sequencing for economic value using Illumina NextSeq™.
Source: PR Newswire
Notable Quotes
- “Access to cost-effective, easy-to-use, distributed NGS kits for liquid biopsy testing are critical to support local laboratories in providing clinically actionable results to oncologists and supporting critical treatment decisions for cancer patients globally.” — Dan Harma, Chief Commercial Officer at Pillar Biosciences
- “We are committed to expanding global patient access to biomarker testing, and decentralized NGS solutions are key to this strategy.” — John Longshore, Head of Scientific Affairs, Global Oncology Diagnostics at AstraZeneca
SoHC's Take
This strategic partnership between Pillar Biosciences and AstraZeneca is a significant development in cancer diagnostics, especially in the European and UK markets. The ability to offer rapid and scalable Next Generation Sequencing (NGS) liquid biopsy tumor profiling empowers local laboratories to perform complex cancer diagnostics in-house. By reducing turnaround times from weeks to just a few days, Pillar’s oncoRevealTM LBx panels not only increase efficiency but also enhance clinical decision-making. This collaboration highlights the importance of decentralized testing in improving global access to precision oncology treatments.
Heading
Key Highlights Shore Capital Partners launches Agentis Longevity to lead the longevity healthcare sector. Jimmy St Louis named CEO, bringing expertise from Regenerative Medicine ...
Key Highlights Nymbl Systems announces strategic partnership with Frontier Growth to accelerate growth and innovation. Frontier Growth brings 25+ years of growth equity expertise to ...
Key Highlights Launch of fingertip blood collection technology using BD’s MiniDraw™ and Babson’s BetterWay for U.S. health systems. Revolutionizes access with fewer ...
Key Highlights Anatomy Financial raises $19M in Series A funding, led by Canapi Ventures. Neil Underwood (Canapi) and Nicole Quinn ...
Key Highlights Wendy Barnes to assume role as GoodRx CEO on January 1, 2025. Brings 30+ years of leadership in pharmacy and healthcare benefit industries. Former CEO of RxBenefits and President of Express ...
Key Highlights Mike Butler, former Providence president, joins Linus Health's board of directors. Butler brings decades of healthcare leadership and ...
